Home
RNA Therapeutics USA

JUST ANNOUNCED: END OF DAY 1 NETWORKING DRINKS RECEPTION

This year, for the first time ever, RNA Therapeutics is in association with AI in Drug Discovery USA to create Drug Discovery Week. From October 21-25, 2024, as part of SAE Media Group’s renowned series of conferences, we will unite top experts from major pharma and biotech companies to network and share insights, advancing the development and application of RNA Therapeutics and AI solutions.


Explore the latest advances in RNA therapeutics, analytical and control processes, and vaccine development. Gain access to cutting-edge innovations in delivery technologies for precision targeting, with case studies on LNPs and more. Discover how AI can optimize drug discovery and delivery platforms, as well as formulation strategies to enhance therapeutic success.


Special offer! Purchase both an RNA Therapeutics USA ticket and an AI USA pass to receive 50% off both purchases. Book your tickets here—simply fill out our short form, and a team member will contact you to discuss your needs. Please note: this offer is for new bookings only and cannot be used in conjunction with other offers.
 

FEATURED SPEAKERS

Derek O Hagan

Derek O Hagan

Senior Advisor R&D, GSK
Hetal Patel

Hetal Patel

Senior Principle Scientist/Group Leader, Pfizer
Jason Zhang

Jason Zhang

Co-Founder and CEO, Zipcode Bio
Jay Sarkar

Jay Sarkar

Researcher and Entrepreneur, Stanford University
Kevin Kim

Kevin Kim

VP, Discovery, miRecule, Inc.
Kinkini Roy

Kinkini Roy

Associate Director, Aviceda Therapeutics
Martin Akerman

Martin Akerman

CTO & Co-Founder, Envisagenics
Pushkar Saralkar

Pushkar Saralkar

Senior Scientist, Pfizer
Richard Geary

Richard Geary

EVP, Chief Development Officer, Ionis Pharmaceuticals, Inc.
Sandy Hinckley

Sandy Hinckley

VP, Head of Discovery, QurAlis Corporation
Sourav Choudhury

Sourav Choudhury

Head AAV Technologies, Sanofi
Steve Pascolo

Steve Pascolo

Founder and CEO, Miescher Pharma GmbH
Sudhir Agrawal

Sudhir Agrawal

Founder and President, ARNAY Sciences
Yue Hui

Yue Hui

Scientist, Moderna
Zdravka Medarova

Zdravka Medarova

Chief Scientific Officer, TransCode Therapeutics
Zimeng Wang

Zimeng Wang

Senior Scientist, AstraZeneca

Derek O Hagan

Senior Advisor R&D, GSK
Derek O Hagan

I am currently a Senior Advisor in GSK Vaccines R&D. Prior to my current role I was the Global Head of Discovery Support and New Technology in GSK. Previously, I was VP, Global Head of Vaccine Chemistry and Formulation for Novartis Vaccines. I have extensive experience on Vaccine Adjuvants, including R&D on several included in licensed products, and I was a member of the Team that initiated work on RNA vaccines in Novartis in 2009. I am a Fellow of the American Association of Pharmaceutical Scientists. I was previously awarded the Conference Science medal of the Royal Pharmaceutical Society of Great Britain, and the Young Investigator Research Achievement Award of the Controlled Release Society. I was named as the ‘most inventive scientist’ in Chiron Corp, Emeryville.

  • 175 peer reviewed publications (h-index 105, Google Scholar)
  • Named inventor on >70+ patents
     

Hetal Patel

Senior Principle Scientist/Group Leader, Pfizer
Hetal Patel

I am a group leader/Senior Principal Scientist at Pfizer Analytical Research and Development managing early and late-stage method validation and transfers.
I have a masters in organic chemistry, Ph.D. in protein chemistry/biochemistry from Rutgers University and Postdoctoral from Albert Einstein, NY. I pursued MBA in management from Babson (finance, leadership excellence, people management) during my tenure at Pfizer.
I have hands on experience working with mAbs, mRNA, small molecules, including small molecule synthesis, protein expression, variety of chromatographic/spectroscopic techniques, biochemical and biophysical characterization technologies, GMP inspections/audits, regulatory submissions/query responses. Lately, I have been actively leading implementation of ICH Q2 (R2) and ICH Q14 approaches around using prior knowledge and abbreviated validations in late-stage mRNA and mAb product development.
 

Jason Zhang

Co-Founder and CEO, Zipcode Bio
Jason Zhang

Dr. Jason Zhang is the Co-Founder and CEO of Zipcode Bio, a leading biotechnology company developing next-generation nucleic acid-based medicines. Before founding Zipcode Bio, he was CSO at two biotech firms, overseeing preclinical R&D and pipeline strategy. Dr. Zhang has broad expertise in oncology, immunology, neurology, and infectious diseases, working with therapeutic modalities like mRNA, AAV, antibodies, and oligonucleotides.
He has successfully advanced multiple drug candidates through clinical trials and contributed to a marketed drug. Dr. Zhang also brings extensive experience in business development and alliance management. He holds dual PhDs in Immunology (NYU) and Chemistry (Peking Union Medical College), and completed postdoctoral training at Yale and Harvard, as well as a CEO program at Haas School of Business.
 

Jay Sarkar

Researcher and Entrepreneur, Stanford University
Jay Sarkar

Dr. Sarkar is a researcher and entrepreneur with a background in applied physics and electrical engineering, which he utilizes to develop systems biology solutions for medicine. He built his first company off his foundational PhD work at Stanford University, where he pioneered the use the mRNA modality for transiently reprogramming cell epigenetics to specifically reset cellular age. The approach has grown as one of the hottest in the longevity community, with some of the largest startup investments in biotech history. He has now progressed to studying the broader problem of new modality integration and distribution in a variety of tissues.

Kevin Kim

VP, Discovery, miRecule, Inc.
Kevin Kim

Kevin is an experienced leader in RNA therapeutic discovery with a track record of successfully managing research organizations and executing multiple pipeline programs to overcome technical and developmental challenges to bring RNA therapies to the clinic for genetic disorders.
Kevin received his doctoral degree at UCLA and worked with the world-renowned experts on neuromuscular diseases, Dr. Lee Rubin at Harvard University and Dr. Robert Baloh at Cedars- Sinai Hospital, to unravel the disease mechanisms and potential therapeutic pathways for devastating diseases such as ALS and CMT. Over a decade of experience in academia and in various industry settings (start-up, biotech and pharma) has culminated in multiple academic publications and patents as well as contribution to the development of the next generation stereopure ASO drugs for CNS diseases (Wave Life Sciences) and cardioprotective therapeutic (Stem Cell Theranostics) which are currently undergoing preclinical and clinical evaluations. As Senior Director of Discovery Biology at Sarepta Therapeutics, Kevin and his team enhanced the delivery of FDA-approved PMO platform and expanded the utility of the platform to discover novel RNA therapeutics for genetic diseases. Kevin is currently serving as VP of Discovery at miRecule, Inc.
 

Kinkini Roy

Associate Director, Aviceda Therapeutics
Kinkini Roy

After finishing PhD and postdoc study from University of Massachusetts Amherst, Kinkini Roy worked in industry for last 12 years in Boston Biotech as well as big corporation. Currently she is leading the program for the next-generation RNA therapeutics using a proprietary synthetic, high-affinity, multi-valent glycans that target extrahepatic cells and improve intracellular delivery and efficacy of siRNA, Anti- sense oligonucleotides, mRNA-based therapeutics, Crispr-Cas9 gene editing and lysosomal targeted protein degradation. Along with that she is leading the formulation development team and develop the formulation development strategy for pipeline development.

Martin Akerman

CTO & Co-Founder, Envisagenics
Martin Akerman

Dr. Martin Akerman is the inventor of SpliceCore®, Envisagenics’ flagship platform born of his vision of applying machine learning to RNA information and discovering new drug targets in areas of unmet need. Martin trained as a postdoctoral fellow with Dr. Adrian Krainer at Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. Dr. Akerman received his PhD in Bioinformatics from Technion, Israel Institute of Technology, where he studied how RNA splicing can boost functionality of the human genome and trigger diseases.

Pushkar Saralkar

Senior Scientist, Pfizer
Pushkar Saralkar

Pushkar Saralkar is a Senior Scientist at Pfizer within the BioTherapeutics Pharmaceutical Research & Development organization in Andover, MA. Dr Saralkar is experienced in drug product development, with a particular interest in mRNA lipid nanoparticles. His research is broadly focused on developing delivery solutions to advance novel therapeutics into the clinic and is driven by developing breakthroughs that can change patient's lives.

Dr Saralkar completed a Ph.D. (Pharmaceutical Science) in 2021 at West Virginia University with focus in nanoparticle-based drug delivery, CNS targeting and BBB pharmacokinetics. His research targeted mitochondrial protein mitoNEET to improve tissue survival following cerebral ischemia and reperfusion injury.
 

Richard Geary

EVP, Chief Development Officer, Ionis Pharmaceuticals, Inc.
Richard Geary

Dr. Geary is the Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 50 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led six successful antisense medicine development programs through approvals in multiple jurisdictions.
During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts.
 

Sandy Hinckley

VP, Head of Discovery, QurAlis Corporation
Sandy Hinckley

Sandy Hinckley, Ph.D., is an accomplished drug-discovery scientist with a background as a human stem cell biologist and neuroscientist, focusing on disease modeling, therapeutic discovery, and translational research. Dr. Hinckley is currently vice president, head of discovery at QurAlis Corporation, a biotech company at the forefront of discovering and developing transformative precision medicines for neurodegenerative diseases, where she leads QurAlis' drug discovery efforts and biomarker strategies. She has worked at QurAlis since 2018, bringing forward two programs into clinical studies, including QRL-201, a splice-switching oligonucleotide for restoring STATHMIN-2 in sporadic ALS and other neurodegenerative diseases.

Sourav Choudhury

Head AAV Technologies, Sanofi
Sourav Choudhury

Sourav Choudhury is a Lab Head in the Genomics Medicine Unit at Sanofi, based in Framingham, MA. He joined Sanofi in 2020 to lead AAV Technologies Laboratory, a platform group focused on AAV capsid engineering and AAV immunology.
Sourav obtained his Ph.D. from UMASS Medical School for his work on development of novel CNS-tropic AAV capsids. He did his postdoctoral training in the laboratory of Feng Zhang at Broad Institute, demonstrating the first in vivo application of CRISPR nuclease Cas12a. Sourav has since worked in Cambridge-based early stage biotechs, first at Intellia Therapeutics designing AAV-based genome editing tools, and then at LogicBio Therapeutics, where he led early-discovery stage indication selection.
 

Steve Pascolo

Founder and CEO, Miescher Pharma GmbH
Steve Pascolo

Trained as an immunologist at the Pasteur Institute (Paris, France), Prof. Steve Pascolo started working on mRNA vaccine in 1998 in Tuebingen, Germany. In 2000, he co-founded CureVac and was Chief Scientific Officer (CSO) of the company, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of synthetic mRNA and starting in 2003 the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he left CureVac and continued the development of immunotherapies based on RNA at the University Hospital of Zurich. In 2008, he founded Miescher Pharma to support this work. In 2017, Prof. Pascolo implemented in the University of Zurich an academic mRNA platform. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.

Sudhir Agrawal

Founder and President, ARNAY Sciences
Sudhir Agrawal

Sudhir Agrawal, D. Phil., FRSC, is the founder and President of ARNAY Sciences. He also serves as an Affiliate Professor in the Department of Medicine at UMass Chan Medical School. Over the last three decades, his research interest has been discovering and developing RNA therapeutics, including antisense and immunotherapy. He focuses on the chemical biology of nucleic acids for creating RNA therapeutics. He has published over 300 research papers and is listed as a co-inventor of more than 500 patents worldwide. He has edited four books on oligonucleotides and antisense technology, including a recent book on ‘Advances in Nucleic Acid Therapeutics’ by The Royal Society of Chemistry. He is currently serving as a member of the scientific advisory board of several biotechnology companies.

He obtained his D.Phil. in Chemistry from Allahabad University in India and conducted postdoctoral research at MRC’s Laboratory of Molecular Biology, Cambridge, UK. His research in the antisense field started in Paul Zamecnik’s laboratory at the Worcester Foundation of Experimental Biology, now UMass Chan Medical School. He was a co-founder of Idera Pharmaceuticals and held various roles until 2017.

In 2022, the Oligonucleotide Therapeutic Society awarded him the Lifetime Achievement Award.

 

Yue Hui

Scientist, Moderna
Yue Hui

I earned my Ph.D. degree in Chemical Engineering from Caltech under Professor David A. Tirrell. In September 2022, I joined Moderna as a Scientist in Formulation Discovery. Here, I lead research initiatives focused on LNP process fundamentals and innovation, as well as novel LNP systems for both hepatic and extra-hepatic delivery of nucleic acids.

Zdravka Medarova

Chief Scientific Officer, TransCode Therapeutics
Zdravka Medarova

Zdravka Medarova, PhD has served as Scientific Co-Founder and a member of the advisory board of TransCode since January 2016. Dr.
Medarova has been on the Faculty of Harvard Medical School and MGH since June 2007. She has served as an Associate Professor of Radiology at Harvard Medical School from April 2016 and as an Assistant in Neuroimaging at the Athinoula A. Martinos Center for Biomedical Imaging at MGH since June 2007. Dr. Medarova joined TransCode fulltime as the Chief Technology Officer on October 1, 2021. Dr. Medarova is a geneticist/cancer biologist by training and is internationally recognized for her work on non-coding RNA for cancer therapy. She is one of the first to describe the design and application of nanoparticles as carriers of siRNA to tumors. Since then, her research has focused on developing nanotechnology and imaging tools to better understand cancer initiation and progression and applying this knowledge to design clinically relevant therapeutic and diagnostic agents against cancer. Dr. Medarova obtained a B.A. in pre-medicine from the University of Southern Maine in September 1998 and a Ph.D. in Genetics from the University of New Hampshire in December 2002.

Zimeng Wang

Senior Scientist, AstraZeneca
Zimeng Wang

Zimeng is a senior scientist of Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca. His research in AZ includes formulation optimization to enhance the efficacy and safety of LNP vaccines, development of dry powder LNPs to improve RT stability, and development of LNPs for local/targeted delivery. Before joining AZ, he worked in Phosphorex Inc. on development of sustained release microspheres and targeted delivery nanoparticles. Zimeng got his PhD in University of Rhode Island focusing on development of dry powder aerosol nanocomposite microparticles for the treatment of pulmonary diseases.

Whether you're new to the RNA space or at the forefront of RNA innovation, our 2-day conference is designed to meet your needs with a comprehensive agenda exploring the latest in RNA research and development.

  • Engage, Collaborate, and Learn: Connect with peers to exchange ideas, collaborate on projects, and learn from both the successes and challenges in RNA discovery, development, delivery, and manufacturing.
  • Stay Ahead of the Curve: Dive into sessions covering breakthroughs in mRNA technology, innovative delivery systems, and cutting-edge therapeutic applications. Gain insights from leading pharmaceutical companies such as Pfizer, Moderna, Sanofi, and AstraZeneca.
  • Drive Innovation: Participate in discussions on the future of RNA therapeutics, including the role of AI and machine learning in drug discovery and development. Learn how to overcome current challenges and leverage new opportunities to stay competitive in this fast-evolving field.

Join us in October!
 

Who Should Attend?

Join us at RNA Therapeutics USA and immerse yourself in a hub of innovation and expertise. Engage directly with top-tier professionals including Directors, Heads, and Principal Scientists specializing in RNA Drug Delivery/Development, Genetic Medicine, Analytical Development, CMC/Manufacturing, and Drug Discovery. This event offers a rare platform to delve into the latest scientific breakthroughs, explore cutting-edge technologies, and discuss strategic insights with pioneers shaping the future of RNA therapeutics. Elevate your knowledge, spark new ideas, and discover collaborative opportunities that can accelerate your research and development projects.

sponsors

Why not partner with us?

By sponsoring, you’ll position your brand for success. Don't miss out on the opportunity to elevate your visibility, credibility, and business prospects—consider sponsorship today!

Please contact Yasmin Alsadoon at Yasmin.Alsadoon@saemediagroup.comor call +44 (0) 20 7827 6064

Conference agenda

clock

8:00

Registration & Coffee

clock

9:00

Chair's Opening Remarks

Martin Akerman, CTO & Co-Founder, Envisagenics

clock

9:10

Opening Address: Advancements in Antisense Therapy for Neurological Disorders

Richard Geary, EVP, Chief Development Officer, Ionis Pharmaceuticals, Inc.

  • Utilising antisense technology to broaden therapeutic scope
  • Case studies: nusinersen (Spinraza) in spinal muscular atrophy (SMA) for spinal muscular atrophy and tofersen (Qalsody) in ALS with SOD1
  • mutations
  • Opportunities in applying antisense technology as potential therapy for other neurodegenerative diseases and neurodevelopmental disorders
  • clock

    9:50

    Cyclic structured oligonucleotides for RNA therapeutics

    Sudhir Agrawal, Founder and President, ARNAY Sciences

  • Sequence and chemistry are critical factors in providing drug-like properties to oligonucleotide
  • In the early days, chemistry addressed the nuclease stability and affinity and allowed the design of gapmer antisense and modified RNA for splice modulation
  • The discovery of Pattern Recognition receptors (PRRs) provided insights into immune activation by oligonucleotides, and SAR studies provided details on modifications to mitigate immune activation.
  • New generations of antisense are designed using lessons learned during studies with PRRs, shapes, and useful chemical modifications
  • Transient cyclic structures of oligonucleotide provide efficient delivery of therapeutics to cellular compartments, resulting in increased potency and specificity
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Recent Advances in the Development of Splice-Switching Oligonucleotides for CNS Diseases

    Sandy Hinckley, VP, Head of Discovery, QurAlis Corporation

  • Pre-mRNA mis-splicing is a recurring theme in neurodegenerative diseases
  • Splice switching ASOs provide a powerful modality to correct these errors
  • QurAlis’ FlexASO™ platform enables the construction of splice switching ASOs with enhanced potency, safety, and biodistribution properties
  • This platform generally and in the context of our discovery programs will be discussed
     
  • clock

    11:40

    RNA Therapeutics development with AI/ML

    Martin Akerman, CTO & Co-Founder, Envisagenics

  • Introducing SpliceCore, an AI-driven platform developed by Envisagenics, tailored to uncover novel therapeutic targets for neurodegenerative diseases like ALS, leveraging the intricate process of alternative splicing which is crucial in neuronal function and disease
  • Decoding ALS with SpliceCore: We will explore the scientific premise of alternative splicing, and the use of AI/ML to develop splicing modulatory drugs to treat sporadic ALS
  • SpliceCore’s predictive power has been validated experimentally, demonstrating its efficacy in identifying novel antisense drug targets for neurodegeneration
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Key Considerations for Targeted Delivery of RNA

    Kinkini Roy, Associate Director, Aviceda Therapeutics

  • Importance of targeted delivery for maximizing therapeutic efficacy and minimizing off-target effects
  • Strategies and technologies to achieve controlled and efficient targeted RNA delivery
  • Active vs. Passive Targeting: Comparing targeting methods, their mechanisms, advantages, and applications in RNA therapeutics
  • Major obstacles in targeted RNA delivery and potential ways to address these challenges
  • clock

    14:00

    Development of 3-component LNP with fast shedding off PEG copolymer coating

    Zimeng Wang, Senior Scientist, AstraZeneca

  • PEG-lipid in LNP brings “PEG dilemma”: (1) PEG-lipid is essential to achieve desired LNP size during fabrication and maintain the colloidal stability during storage; (2) PEG-lipid could reduce the cell uptake and induce PEG-specific antibodies increasing the clearance rate of PEGylated LNP
  • PEG copolymer coating could be a potential solution to “PEG dilemma”, which maintains particle size during storage but sheds off quickly after administration to improve the in vivo efficacy
  • In this study, we optimized both the fabrication process and LNP composition to ensure desired physicochemical properties and efficacy of poloxamer 407 (P407) coated LNP
  • In vivo study using luciferase mRNA showed initial P407 coated formulation led to increased spleen and lung mRNA distribution comparing to the LNP with PEG-lipid. However, lower luciferase protein level in organs indicated that further optimization is required to improve the LNP efficacy
  • The optimized LNP with increased phospholipid ratio significantly improved the in vitro efficacy of P407 coated LNP
  • clock

    14:40

    Afternoon Break

    clock

    15:10

    Optimizing RNA Therapeutics: ML-Powered Development, Novel Delivery Platforms, and Pipeline Expansion

    Jason Zhang, Co-Founder and CEO, Zipcode Bio

  • Utilizing advanced machine learning models to accelerate design and optimization, enabling faster and more precise development of RNA-based therapies.
  • Pushing the front of mRNA medicines via traditional LNPs and novel SHARP platform to redefine the landscape of mRNA delivery for enhanced therapeutic efficacy.
  • Unveiling Zipcode Bio’s immunology pipeline including innovative mRNA vaccines and therapeutics
     
  • clock

    15:40

    Novel Constructs for Network Mediated Large Molecule Drug Delivery

    Jay Sarkar, Researcher and Entrepreneur, Stanford University

  • Drug Routers and the Network Paradigm for Drug Delivery
  • Analysis of Router Induced Networks
  • Distributable Cargo and Cell Type Diversity
  • In Vivo Delivery and Continuing Studies
  • clock

    16:20

    Chair’s Closing Remarks and Close of Day One

    Martin Akerman, CTO & Co-Founder, Envisagenics

    clock

    16:25

    End of Day One Networking Drinks Reception

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chair's Opening Remarks

    Sourav Choudhury, Head AAV Technologies, Sanofi

    clock

    9:10

    Advancing Gene Delivery Vehicles with AI/ML

    Sourav Choudhury, Head AAV Technologies, Sanofi

  • Insight into use of viral delivery platforms for improved delivery
  • Opportunities to advance capsid development and further understand capsid functioning through use of AI
  • Examples of machine learning guided capsid development
  • clock

    9:50

    mRNA process science and engineering: first steps towards a novel modality

    Yue Hui, Scientist, Moderna

  • mRNA as a new modality for vaccines and therapeutics
  • Fundamentals on LNP assembly: understanding the impact of fluid dynamics
  • A case study on CMV vaccine
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Formulation considerations for mRNA-lipid nanoparticles: vaccines and beyond

    Pushkar Saralkar, Senior Scientist, Pfizer

  • Formulation aspects of lipid nanoparticles that enabled the success of mRNA as a vaccine
  • Challenges in formulation and process parameters during product development of mRNA-lipid nanoparticles
  • Considerations when designing mRNA-lipid nanoparticle drug products as a therapeutic vs. vaccine
  • clock

    11:40

    Practical Application of Platform Analytical Procedures in Late-Stage Development of mRNA

    Hetal Patel, Senior Principle Scientist/Group Leader, Pfizer

  • Practical applications of platform analytical procedures leveraging guidance from ICH Q2 (R2) and ICH Q14 and the challenges associated with this paradigm shift
  • Using prior knowledge, experience and historical data to expand the application of platform analytical procedures to reduce redundant work and enable a strong scientific justification for approach to an abbreviated validation in late-stage
  • How prior knowledge including method validation and transfer may be used to enable rapid commercial readiness with streamlined approach
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    The role of adjuvants in vaccine development

    Derek O Hagan, Senior Advisor R&D, GSK

  • Reviewing the mechanisms and science behind adjuvants, and how they enhance immune responses
  • Exploring the potential of adjuvants to improve the performance of RNA vaccines
  • Future outlook: what will the next generation of adjuvants look like?
  • clock

    14:00

    mRNA Vaccines: The past, present and future directions for advancing

    Steve Pascolo, Founder and CEO, Miescher Pharma GmbH

  • History of mRNA vaccines and how they have developed since COVID-19
  • Insight into the mode of action of synthetic vs natural mRNA vaccines
  • Effective formulation and production strategies to implement for mRNA vaccine development
  • Evaluating the current vaccines and therapies based on synthetic mRNA currently in the market and the key takeaways
  • clock

    14:40

    Afternoon Break

    clock

    15:10

    Fireside Chat: The Future of RNA Therapeutics: Innovations, Technologies, and Modalities

  • Exploring the potential next wave of RNA-based therapeutics oised to hit the market. What are the technologies and research areas that the industry should prioritize and develop?
  • Platforms for developing delivery vectors: latest platforms and strategies for creating effective and reliable delivery vectors
  • Future opportunities for furthering innovation and strategic collaborations
  • Sourav Choudhury, Head AAV Technologies, Sanofi

    Steve Pascolo, Founder and CEO, Miescher Pharma GmbH

    Kevin Kim, VP, Discovery, miRecule, Inc.

    clock

    15:50

    Chair’s Closing Remarks and Close of Day Two

    Sourav Choudhury, Head AAV Technologies, Sanofi


    Senior Advisor R&D
    GSK
    Senior Principle Scientist/Group Leader
    Pfizer
    Co-Founder and CEO
    Zipcode Bio
    Researcher and Entrepreneur
    Stanford University
    VP, Discovery
    miRecule, Inc.
    Associate Director
    Aviceda Therapeutics
    CTO & Co-Founder
    Envisagenics
    Senior Scientist
    Pfizer
    EVP, Chief Development Officer
    Ionis Pharmaceuticals, Inc.
    VP, Head of Discovery
    QurAlis Corporation
    Head AAV Technologies
    Sanofi
    Founder and CEO
    Miescher Pharma GmbH
    Founder and President
    ARNAY Sciences
    Scientist
    Moderna
    Chief Scientific Officer
    TransCode Therapeutics
    Senior Scientist
    AstraZeneca

    Exhibitors

    Supporters

    SAE Group Media is delighted to confirm that AI USA is now in association with RNA Therapeutics USA and together they form Drug Discovery Week.

    What’s more, when you secure your ticket to AI USA and your colleague books for RNA USA, you will receive a 50%* discount across both tickets – confirm your attendance to both events below!

    50% Off Tickets

    *Please note: This offer is for new bookings only and cannot be used in conjunction with other offers. For full terms and conditions, click here

    AI in Drug Discovery USA

    AI in Drug Discovery USA

    Courtyard by Marriott Boston Downtown
    21 October - 22 October 2024
    , USA

    Video Speaker Interview - Jim Weterings

    Download

    Past Attendee List

    Download

    Brochure

    Download

    Speaker Interview - TRANSCODE THERAPEUTICS

    Download

    Past Presentation - HDT Bio

    Download

    Past Presentation - Avidity

    Download

    Exhibitors


    ChemGenes

    Exhibitors
    http://www.chemgenes.com

    ChemGenes, an ISO 9001 certified company established in 1981, is the industry leader in manufacturing oligonucleotide synthesis reagents and has consistently provided the highest quality phosphoramidites and solid supports in the market. Our facility, just outside of Boston/Cambridge Massachusetts USA, is setup for bulk manufacturing of therapeutic grade phosphoramidite and solid support DNA/RNA synthesis products for GMP grade oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of modified phosphoramidites and supports currently used in oligonucleotide synthesis including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing you with invaluable customer service and comprehensive technical support.


    TriLink BioTechnologies

    Exhibitors
    https://www.trilinkbiotech.com/

    TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.


    Media Partners


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    The Medicine Maker

    Supporters
    https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo

    The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo

    Courtyard by Marriott Boston Downtown


    USA

    Courtyard by Marriott Boston Downtown

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.